4N7Y image
Deposition Date 2013-10-16
Release Date 2014-02-19
Last Version Date 2023-11-15
Entry Detail
PDB ID:
4N7Y
Title:
Crystal structure of 14-3-3zeta in complex with a 8-carbon-linker cyclic peptide derived from ExoS
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.16 Å
R-Value Free:
0.25
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:14-3-3 protein zeta/delta
Gene (Uniprot):YWHAZ
Chain IDs:A, B
Chain Length:235
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Exoenzyme S
Gene (Uniprot):exoS
Mutations:L422(2JN),A425(MK8)
Chain IDs:C, D
Chain Length:11
Number of Molecules:2
Biological Source:Pseudomonas aeruginosa
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
MK8 C LEU 2-METHYL-L-NORLEUCINE
Primary Citation
Constrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein-protein interaction.
Angew.Chem.Int.Ed.Engl. 53 2489 2493 (2014)
PMID: 24504455 DOI: 10.1002/anie.201310082

Abstact

Bioactive conformations of peptides can be stabilized by macrocyclization, resulting in increased target affinity and activity. Such macrocyclic peptides proved useful as modulators of biological functions, in particular as inhibitors of protein-protein interactions (PPI). However, most peptide-derived PPI inhibitors involve stabilized α-helices, leaving a large number of secondary structures unaddressed. Herein, we present a rational approach towards stabilization of an irregular peptide structure, using hydrophobic cross-links that replace residues crucially involved in target binding. The molecular basis of this interaction was elucidated by X-ray crystallography and isothermal titration calorimetry. The resulting cross-linked peptides inhibit the interaction between human adaptor protein 14-3-3 and virulence factor exoenzyme S. Taking into consideration that irregular peptide structures participate widely in PPIs, this approach provides access to novel peptide-derived inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures